- Home
- / Progenics Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Progenics Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$35 M
FY, 2019
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.8M | 14.0M | 7.9M | 44.4M | 8.7M | 69.4M | 11.7M | 15.6M | 35.0M |
| Cost of goods sold | 3.2M | ||||||||
| Gross profit | 31.8M | ||||||||
| Gross profit margin, % | 90.9% | ||||||||
| General and administrative expense | 18.2M | 14.7M | 14.8M | 14.9M | 18.2M | 23.4M | 24.9M | 29.4M | 47.8M |
| Operating expense total | 18.8M | 48.6M | 48.7M | 42.7M | 46.4M | 60.9M | 67.5M | 64.6M | 98.0M |
| Depreciation and amortization | 939.0K | 545.0K | |||||||
| EBIT | 10.3M | (35.5M) | (43.0M) | 3.4M | (39.3M) | 13.1M | (58.4M) | (66.4M) | (66.2M) |
| EBIT margin, % | 12.2% | -252.6% | -546.7% | 7.6% | -453.0% | 18.9% | -499.2% | -424.8% | -189.1% |
| Interest income | 65.0K | 60.0K | 46.0K | 51.0K | 52.0K | ||||
| Interest expense | 65.0K | 60.0K | 46.0K | 51.0K | 52.0K | 493.0K | 4.3M | 2.9M | 2.4M |
| Pre tax profit | 10.4M | (35.4M) | (42.9M) | 3.4M | (39.3M) | 12.6M | (62.7M) | (69.3M) | (68.5M) |
| Income tax expense | (362.0K) | (989.0K) | (133.0K) | 1.8M | (11.7M) | (1.6M) | 17.0K | ||
| Net Income | 10.4M | (35.4M) | (42.6M) | 4.4M | (39.1M) | 10.8M | (51.0M) | (67.7M) | (68.6M) |